Unicycive Therapeutics (UNCY) Investor Presentation - Slideshow

Unicycive Leadership Board of Directors Brigitte Schiller, MD SVP, Medical Officer, Fresenius Medical Care Scientific Advisory Board $130 Million in Long-Term Financing RENAZORB □ NDA filing in mid 2023 ✓ Animal safety studies completed □ FDA IND filing for Phase 2 POC study Investor Relations Novel Treatments for Kidney Disease Un NASDAQ: UNCY Company Presentation March 2023 Forward Looking Statements Unique product candidates with proven mechanisms of action · RENAZORB™(lanthanum dioxycarbonate) is an inv ...